HER۲ Amplification in Non-Mutant RAS Status in Patients with Metastatic Colorectal Cancer and the ۲-Year Survival Rate

سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 110

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_TBSRJ-5-2_001

تاریخ نمایه سازی: 9 آذر 1402

چکیده مقاله:

Introduction: HER۲ amplification is a therapeutic target in breast and stomach cancer, but the relationship between HER۲ and response to treatment in metastatic colorectal cancer has not been fully determined. This study investigated the incidence of HER۲ overexpression in non-mutant RAS patients with metastatic colorectal cancer to determine the two-year survival rate in patients referred to Imam Khomeini Hospital in Sari between ۲۰۱۴-۲۰۱۸. Material and Methods: This cohort study was conducted between ۲۰۱۴ and ۲۰۱۸ among patients with metastatic colorectal cancer who were identified as non-mutant (wild) NRAS, KRAS, and BRAF genes. Patients received cetuximab. The clinical course of the patients was evaluated simultaneously during this evaluation period, and the two-year survival rate of the patients and the response to cetuximab were evaluated. Data were entered into SPSS software version ۲۴ and analyzed. Results: Twenty-five patients were examined, ۶۰% were men. The most common symptom in patients was abdominal pain (۳۲%). The majority (۷۲%) of the study patients did not undergo surgery, ۲۴% underwent hemicolectomy and ۴% underwent total colectomy. The incidence of HER۲ positive in women was higher than in men (۱۰% vs. ۶%) and in grade ۱ patients was higher than grade ۲ (۸.۳% vs. ۱.۱%). Forty-four percents of patients had positive two-year survival. Among patients with positive two-year survival, ۹.۱% were HER۲ positive and ۹۰.۹% were HER۲ negative. Conclusion: The results of the study showed that infectious causes (influenza) and underlying CLD including asthma were major causes of ARF in pregnant women. Thus, more careful attention is needed to control the underlying disease, and planning for easier access to the influenza vaccine can play an effective role in reducing the incidence of pulmonary infections.

کلیدواژه ها:

نویسندگان

Ehsan Zaboli

Gastrointestinal Cancer Research Center, Non‐Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

Davood Shirazi MajiMiriha

Department of Internal Medicine, School of Medicine, Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, Iran

Farshad Naghshvar

Department of Pathology, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

Reza Alizadeh-Navaei

Gastrointestinal Cancer Research Center, Non‐Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

Masumeh Shirazi HajiMiriha

Department of Internal Medicine, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Garcia M, Jemal A, Ward EM, Center MM, Hao Y, ...
  • Setareh S, Zahiri Esfahani M, Zare Bandamiri M, Raeesi A, ...
  • Esna-Ashari F, Sohrabi MR, Abadi AR, Mehrabian AA, Mofid B, ...
  • Asghari-Jafarabadi M, Hajizadeh E, Kazemnejad A, Fatemi SR. Recognition of ...
  • Guo S, Piao X, Li H, Guo P. Methods for ...
  • Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, ...
  • Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, ...
  • Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic ...
  • Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, ...
  • Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, ...
  • Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, ...
  • Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, ...
  • Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, ...
  • Shibata D, Schaeffer J, Li ZH, Capella G, Perucho M. ...
  • Lievre A, Bachet JB, Boige V, Cayre A, Le Corre ...
  • Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, ...
  • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena ...
  • Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. ...
  • Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, ...
  • Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR ...
  • Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, ...
  • Rau A, Janssen N, Kühl L, Sell T, Kalmykova S, ...
  • Di Nicolantonio F, Martini M, Molinari F, Sartore Bianchi A, ...
  • Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo ...
  • Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, ...
  • Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, ...
  • Martin V, Landi L, Molinari F, Fountzilas G, Geva R, ...
  • Raghav KP, Overman MJ, Yu R, Meric-Bernstam F, Menter D, ...
  • Richman SD, Southward K, Chambers P, Cross D, Barrett J, ...
  • Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-۲/neu ...
  • Venter D, Kumar S, Tuzi N, Gullick W. Overexpression of ...
  • Li W, Zhang X, Du Y, Zhang Y, Lu J, ...
  • Ingold Heppner B, Behrens HM, Balschun K, Haag J, Krüger ...
  • Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, ...
  • Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, ...
  • Sartore‐Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, ...
  • Xie YH, Chen YX, Fang JY. Comprehensive review of targeted ...
  • Perillo F, Amoroso C, Strati F, Giuffrè MR, Díaz-Basabe A, ...
  • Liu R, Zhao X, Guo W, Huang M, Qiu L, ...
  • Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, ...
  • Jeong JH, Kim J, Hong YS, Kim D, Kim JE, ...
  • Safaee A, Dehkordi BM, Fatemi SR, Ghiyasi S, Zali MR. ...
  • نمایش کامل مراجع